Copyright 4S Dawn 2002 Dawn AC Benchmarking Mark Ainsworth 4S Dawn Clinical Software Mark Ainsworth 4S Dawn Clinical Software.

Slides:



Advertisements
Similar presentations
Understanding p-values Annie Herbert Medical Statistician Research and Development Support Unit
Advertisements

September 10, 2008 Medication Safety: Anticoagulation Management Carla S. Huber, ARNP MS Community Anticoagulation Therapy (CAT) Clinic Cedar Rapids, IA.
Audit of warfarin reversal in over-anticoagulated patients D Wright and J Seal Department of Haematology Pontefract General Infirmary Nov 2002.
Mark W Linder, Ph.D., DABCC, FACB Medical Director, EVP Operations Kristen K. Reynolds Ph.D. Associate Medical Director, VP Laboratory Operations Mark.
POC INR Testing Rural and Remote Session 2015 CADTH SYMPOSIUM Janice Mann MD Knowledge Mobilization, CADTH.
Westerham and Sundridge Surgeries GP Practice/PPG Patient Survey Results January 2015 Prepared for Margaret Hickmott-Stapley Confidential: Not to be copied.
A randomized, double-blind study on MD-knee versus HA in patients affected by knee OA: preliminary data from the JOINT study Umberto Massafra Dep of Rheumatology,
1 10 points. AF & Warfarin practice Profile 2011.
Management of A.F. patients with the DawnAC induction module David Hirst MidYorkshire Hospitals NHS Trust.
Massachusetts General Hospital Anticoagulation Management Service Using Dawn AC to Support Safe Management of Anticoagulated Patients Lynn B. Oertel, MS,
Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications Mark Bleackley MEDG 505 March.
Julie Hoang Jane Traynham October, Survey Responses 27 responses to survey Should SDCs develop a standard profile Highest importance SF1 profile.
DEFINING THE DURATION OF ANTICOAGULATION. HOW LONG TO TREAT A DVT?
Preventing Surgical Complications Prevent Harm from High Alert Medication- Anticoagulants in Primary Care Insert Date here Presenter:
Audit “ a critical systematic analysis of the quality of medical care – including outcomes use of resources and quality of life for the patient”
OCS-OASIS Desktop Reports and Graphs Provided by OCS Education E-learning Network Provided by OCS Education E-learning Network.
NEAR PATIENT TESTING, DAWN UPGRADE AND INTO THE COMMUNITY IN THREE MONTHS NEAR PATIENT TESTING, DAWN UPGRADE AND INTO THE COMMUNITY IN THREE MONTHS Barts.
Prevention of Recurrent Venous Thromboembolism N Engl J Med Apr ;348(15) : PREVENT (Warfarin) Trial.
Tarmessia Mckay 6 th period Ms. Wright JOB DESCRIPTIONSKILLS REQUIRED TThey are healthcare professionals who diagnose and treat individuals of all.
Nunavut. Nunavut: Profile Population 30,800 (2006) 9,000 + students (41 schools) 3 education regions 26 District Education Authorities + 1 Francophone.
IN-PATIENT WARFARIN CONTROL at PINDERFIELDS GENERAL HOSPITAL, WAKEFIELD BY PHILIP BOOTH SENIOR B.M.S. ANTICOAGULANT CO-ORDINATOR.
ALI R. RAHIMI, BOBBY WRIGHTS, MD, HOSSEIN AKHONDI, MD & CHRISTIAN M. RICHARD, MSC Clinical Correlation Between Effective Anticoagulants & Risk of Stroke:
Anticoagulants Reducing the risk Amanda Powell & Sue Wooller May 2014.
Measures of Variation For Example: The 11 Workers at a company have the following ages: 27, 39, 40, 22, 19, 25, 41, 58, 53, 49, 51 Order data from least.
GRAPPA Meeting, Oct. 16, 2004 San Antonio, Texas Patient Global Question Alberto Cauli Rheumatology Division University of Cagliari, Italy Director Prof.
Virginia Clough The Chester Anticoagulant Service Countess of Chester Hospital.
Copyright © 2011 Pearson Education, Inc. Putting Statistics to Work.
ITQ Unit 128: Website Software. What does a website contain?
1 32 Benchmarking Sites Dawn AC User Group Meeting 2003 Patient Education Survey January Benchmarking Sites.
1 Syd Stewart and Claire Alexander November 2003 Patient Compliance and Benchmarking.
1 CONFIDENTIAL – DO NOT DISTRIBUTE ARIES mCRC: Effectiveness and Safety of 1st- and 2nd-line Bevacizumab Treatment in Elderly Patients Mark Kozloff, MD.
Update on the Online Conversion Process for AEPSi: Implications for OSEP Reporting.
Is a meta-analysis right for me? Jaime Peters June 2014.
Internal Process Model Monitor Role Competency: Managing Collective Performance.
Warfarin-Specific Medication Charts Do they have a place in Aged Care Facilities? Margaret Jordan a,b Judy Mullan a, Victoria Traynor a a. University of.
Date of download: 6/23/2016 From: The Anticipated Clinical and Economic Effects of 90–90–90 in South Africa Ann Intern Med. Published online May 31, 2016.
Introduction Data Statistical Methods Table 1: Prevalence of Prior Hip Fracture and Incidence of New Hip Fractures and Fractures of Any Type.
The Management of AF Warfarin New anticoagulants 16 Sept 2011.
Net clinical benefit of OAC
Variation in place of death from cancer: studies in South East England Elizabeth Davies, Peter Madden, Victoria Coupland, Karen Linklater, Henrik Møller.
Pharmacy in Public Health: Describing Populations Course, date, etc. info.
Figure 2 Survival curves in the elderly vs. younger patients
Copyright © 2003 American Medical Association. All rights reserved.
Tips Need to Consider When Organizing a College Event
Copyrights apply.
Aug, 2016.
-LIVE Global Activities-
Medication Nonadherence in Gout
Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight change. Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight.
Clinical Application of Therapies Targeting VEGF
A Case Challenge: Anticoagulant Choices for Acute PE
Clinical Assessment, Diagnosis, and Treatment
ماجستير إدارة المعارض من بريطانيا
AQA A 2014.
Antithrombotic Protection in CAD and HF
Background. Advancing the Care of Patients With Moderate to Severe Atopic Dermatitis: A Case-Based Discussion.
(A) Indirectly age-sex-deprivation-ethnicity standardised procedure ratios for combined eye injection procedures (OPCS-4: C794 and C893) by CCG in England,
Trials and Tribulations in VTE: How Do Real-World Data Fit In?
Modern Advances in Glucose Monitoring
Optimizing Insulin Therapy in Primary Care: Basal Plus Incretin Combinations.
Clinical Assessment, Diagnosis, and Treatment
Ronnie Fass, Stephen J. Sontag, Barry Traxler, Mark Sostek 
Improving Adherence to Antiplatelet Therapy After an ACS Event
Atrial fibrillation: Improvement in identification and stroke preventive therapy —Data from the UK Clinical Practice Research Datalink, 2000–2012  A.C.E.
Edmund G. Lowrie  Kidney International 
Type 1 Diabetes: Expanding Options for Adjunctive Oral Therapy With SGLT Inhibitors.
Statistical Process Control
Statistical process control charts of adjusted total direct variable cost per discharge. Statistical process control charts of adjusted total direct variable.
Summary multiple regression charts for (A) PROFAD physical fatigue and (B) PROFAD mental fatigue scores. Summary multiple regression charts for (A) PROFAD.
Statistical Process Control
Presentation transcript:

Copyright 4S Dawn 2002 Dawn AC Benchmarking Mark Ainsworth 4S Dawn Clinical Software Mark Ainsworth 4S Dawn Clinical Software

Copyright 4S Dawn 2002 Dawn AC Benchmarking l Current Position l Future Plans l INR Control

Copyright 4S Dawn 2002 Current Position l 9th Benchmarking Run l 96,000 Patients l 690,000 INRs l 62 Subscribers

Copyright 4S Dawn 2002 Current Position l For every target INR range l 3 statistical profiles l 3 charts l Summary chart l Sample reports on website

Copyright 4S Dawn 2002 Future Plans l Grouping patients l Statistical methods of identifying groups l Performance measures by group l Adjustments for Patient Mix l age l sex l time on treatment

Copyright 4S Dawn 2002 Standardising Measures % Time in Range

Copyright 4S Dawn 2002 Standardising Measures Standardised % Time in Range

Copyright 4S Dawn 2002 INR Control l Better INR Control = Reduced Events l Include events in Benchmarking results l What factors influence INR variation? l Prof. Palareti, Bologna, Italy l Italian Federation of Anticoagulation Clinics l AC Therapy Education is strong factor

Copyright 4S Dawn 2002 INR Control

Copyright 4S Dawn 2002 INR Control l BMJ 2002;325: l INR control has effect on events (QC ?) Worth having good INR control

Copyright 4S Dawn 2002 INR Control l Identify poorly performing patients l Improve their INR control

Copyright 4S Dawn 2002 Summary l Third of Dawn AC sites now subscribe l Next improvements l Grouping patients l Adjusting statistics for patient mix

Copyright 4S Dawn 2002 Dawn AC Benchmarking

Copyright 4S Dawn 2002